BIOS, an AI scientist developed by @bioaidevs, has introduced a groundbreaking pipeline that rapidly identifies ranked therapeutic candidates from a protein target in under an hour and for less than $7. Traditionally, drug discovery was a lengthy process involving batch experiments and high failure rates, but BIOS revolutionizes this by incorporating three AI engines—RFdiffusion3, BoltzGen, and PXDesign—that work simultaneously to generate and filter thousands of drug candidates through six critical gates. This innovative approach also allows direct feedback from physical lab testing to refine future designs, aligning with the industry trend toward automated and integrated drug discovery platforms.

BIOS: BIOS is an AI scientist system designed to automate the drug discovery process from identifying a protein target through to generating ranked therapeutic candidates. It employs multiple specialized AI engines operating in parallel to generate and filter potential molecules before physical validation. The news details BIOS as the first system to fully integrate computational design with robotic wet lab testing in a single closed-loop pipeline.
BioAIDevs: BioAIDevs is the account and development team responsible for creating and deploying the BIOS AI scientist platform focused on accelerating therapeutic design. They recently shipped an updated pipeline that connects AI-generated candidates directly to experimental synthesis and binding assays. This announcement positions BioAIDevs as a leader in building end-to-end AI-experiment workflows for drug discovery.

`json
{
“AI Integration”: “AI systems for drug discovery now combine multiple specialized models in parallel to approach molecular design from different angles and then filter the results to identify promising candidates.”,
“Pipeline Innovation”: “Recent advancements allow direct feedback from physical laboratory testing to be integrated back into AI models, enabling iterative improvements across design cycles.”,
“Drug Discovery Automation”: “The industry is moving towards platforms that seamlessly link computational candidate generation with automated experimental validation in a continuous process.”
}
`